GENINVO Announces Upcoming Version Launch of Shadow™

GENINVO CEO Shweta Shukla, announced the upcoming launch of Shadow™ Version 2. Shweta took this opportunity to thank the team. “I would like to thank our teams for staying on track during these stressful times. While it is easier to lose focus of what is important during COVID-19 pandemic, our teams are working from home and using this as an opportunity to bond with their teammates and collaborate with one another. As we build our business, we continue to work relentlessly, while taking care of our loved ones at this time of need. COVID-19 brought new challenges, but our teams have done a spectacular job in adapting to these unexpected situations and supporting our clients.”

She further added, “We have adapted quickly and successfully with this changing economy and working conditions. We continuously focus on becoming a strong company and even stronger employees that already know how to work productively from home. Taking advantage of best in the class collaborative tools, internal webinars, newsletters, and social posts, we stayed in touch and collaborated. We continue to address the safety of our employees, as business operates as usual.”

We would also like to announce the upcoming launch of Shadow™ Version 2 of data transparency solution. Shadow™  is a leader in automating data and document de-identification and anonymization technology. This robust technology can determine risk for re-identification of patients and determination of data utility after anonymization.

It also can generate an anonymization report. With Version 2, it will be AI/ML enabled and address the need of different health authorities including Health Canada. We are supporting customers with submissions to Health Canada. Additionally, we have more SMEs on our team to support our pharmaceutical clients in agile fashion.

GENINVO has other technologies including DocQC™ for automated QC of documents and ApoGI™, a platform for managing data and metadata while interacting with different functions in pharmaceuticals. GENINVO will continue to enable and support our clients in their journey, working collaboratively to understand the needs of their systems, processes, and current challenges within the Life Sciences industry.

Contact Us​

Skip to content